Portal de Periódicos da CAPES

Evaluating the impact of HIV pre-exposure prophylaxis on pregnancy, infant, and maternal health outcomes in Malawi: PrIMO study protocol

2024; BioMed Central; Volume: 24; Issue: 1 Linguagem: Inglês

10.1186/s12889-024-20029-3

1471-2458

Friday Saidi, Sanya Shah, Madeleine Squibb, Lameck Chinula, Charity Nakanga, Tisungane Mvalo, Mitch Matoga, Agatha Bula, Maganizo Chagomerana, Funny Kamanga, Wiza Kumwenda, Tawonga Mkochi, Gladwell Masiye, I. Moya, Michael E. Herce, S. E. Rutstein, Virginia Thonyiwa, Rose Nyirenda, Victor Mwapasa, Irving Hoffman, Mina C. Hosseinipour,

Adolescent Sexual and Reproductive Health

Incident HIV during the perinatal period significantly impedes elimination of Mother-to-Child HIV Transmission (eMTCT) efforts. Pre-Exposure Prophylaxis (PrEP) effectively reduces HIV acquisition, and new agents like injectable Cabotegravir (CAB-LA) offer potential advantages for pregnant and breastfeeding women. The Pregnancy, Infant, and Maternal health Outcomes (PrIMO) study will compare rates of composite adverse pregnancy outcomes, and infant adverse events, growth and neurodevelopment between mother-infant dyads receiving CAB-LA and those receiving oral PrEP in Malawi.